Percutaneous Transcatheter Occlusion of Acquired Gerbode Defect After TAVR Authors: Alec G. Miller, Andrew Monte, Elizabeth Crinzi, Stanley Fernandez, Vijay S. Iyer, Mohamed Abdel-Aal Ahmed Published: 2026 ABSTRACT BackgroundAcquired Gerbode defect is a rare complication of transcatheter aortic valve replacement (TAVR). Percutaneous transcatheter closure is a reasonable yet challenging approach to management.Case SummaryA 74-year-old man presented with decompensated heart failure after TAVR with a balloon-expanding bioprosthesis (Edwards Sapien). Right heart catheterization revealed left-to-right shunting. Transesophageal echocardiography identified a fistula tract from the left ventricular outflow tract to the right atrium (Gerbode defect). This was closed percutaneously with an Amplatzer atrial septal occluder device (Abbott). Device retrieval and replacement was later required given residual paradevice leak.DiscussionAcquired Gerbode defect is a rare complication of TAVR. There are currently no well-defined predictors, but certain patterns of calcification can be a potential cause. The defect can be successfully closed percutaneously using an atrial septal occluder device.Take-Home MessagesOperators should be aware of the risk of an acquired Gerbode defect after TAVR. Transesophageal echocardiography is required for accurate diagnosis, and the defect can be repaired with a percutaneous transcatheter approach. Take-Home Messages •Acquired LVOT-to-RA defect (type II Gerbode defect) is important to recognize as an early complication of performing TAVR, especially in a heavily calcified annulus.•Percutaneous closure is reasonable in patient of prohibitively high surgical risk. Take-Home Messages •Acquired LVOT-to-RA defect (type II Gerbode defect) is important to recognize as an early complication of performing TAVR, especially in a heavily calcified annulus.•Percutaneous closure is reasonable in patient of prohibitively high surgical risk. •Acquired LVOT-to-RA defect (type II Gerbode defect) is important to recognize as an early complication of performing TAVR, especially in a heavily calcified annulus. Acquired LVOT-to-RA defect (type II Gerbode defect) is important to recognize as an early complication of performing TAVR, especially in a heavily calcified annulus. •Percutaneous closure is reasonable in patient of prohibitively high surgical risk. Percutaneous closure is reasonable in patient of prohibitively high surgical risk. History of Presentation A 74-year-old man with past medical history of coronary artery disease and coronary artery bypass grafting was referred to the structural heart team after transthoracic echocardiography (TTE) showed severe aortic stenosis. He underwent multidisciplinary evaluation including consultation with the cardiac surgery team, and he was deemed at prohibitively high risk for redo surgery and surgical aortic valve replacement. He was determined to be an appropriate candidate for a transcatheter aortic valve replacement (TAVR). The patient underwent successful TAVR via the usual percutaneous transfemoral approach with a 29-mm balloon-expandable bioprosthesis (Edwards Sapien 3 Ultra Resilia). At the 2-week follow-up appointment, he reported worsening dyspnea, fatigue, and overall functional decline since the procedure. He was started on diuretics, referred to a cardiac rehabilitation program, and a follow-up TTE was obtained showing a decrease in ejection fraction to 40% to 45% as well as new severe tricuspid regurgitation (TR) (Figure 1). Symptoms continued to worsen, and at the 10-week postoperative appointment, repeat blood work showed a significant increase in creatinine to 3.0 mg/dL (baseline: 1.1 mg/dL). The patient was admitted to the hospital. Examination findings on admission were pertinent for an irregularly irregular rhythm, predominant holosystolic murmur at the lower left sternal border, jaundice, and significant anasarca with pitting edema to the knees bilaterally.Figure 1Transthoracic Echocardiography After TAVR(Left) Four-chamber view and (Right) parasternal short-axis view at the level of the aortic valve showing new “severe tricuspid regurgitation.” Flow across the Gerbode defect was mistaken for eccentricity of tricuspid regurgitation. TAVR = transcatheter aortic valve replacement. Transthoracic Echocardiography After TAVR (Left) Four-chamber view and (Right) parasternal short-axis view at the level of the aortic valve showing new “severe tricuspid regurgitation.” Flow across the Gerbode defect was mistaken for eccentricity of tricuspid regurgitation. TAVR = transcatheter aortic valve replacement. Past Medical History The patient had a history of coronary artery disease with subsequent coronary artery bypass grafting. He had a remote history of morbid obesity with obstructive sleep apnea, but he had lost a significant amount of weight, and he had permanent atrial fibrillation but was not taking anticoagulants because of recurrent gastrointestinal bleeding. Differential Diagnosis Considerations included acute kidney injury due to acute decompensated heart failure, right ventricular failure with TR, and failure of the bioprosthetic TAVR valve. Investigations During hospitalization, a repeat TTE revealed normal functioning bioprosthetic aortic valve with a mean gradient of 6 mm Hg and calculated valve area of 3.4 cm2; hyperdynamic left ventricle (LV) with an ejection fraction of >75%, severe TR, and a large, circumferential pericardial effusion (Figure 2).Figure 2Transthoracic Echocardiography Apical 4-Chamber View Showing Interval Development of Pericardial Effusion During Initial HospitalizationColor Doppler across the tricuspid valve shows the shunt from the Gerbode defect. Transthoracic Echocardiography Apical 4-Chamber View Showing Interval Development of Pericardial Effusion During Initial Hospitalization Color Doppler across the tricuspid valve shows the shunt from the Gerbode defect. The patient responded poorly to diuretics with worsening kidney function, atrial fibrillation with rapid ventricular response and relative hypotension, and development of anemia, with work-up revealing significant hemolysis. He was transferred to the cardiac critical care unit and required vasopressor support. Pericardiocentesis was performed, and a pericardial drain was placed. Right heart catheterization showed pulmonary artery pressures of 54/29/38 mm Hg (systolic/diastolic/mean) and pulmonary artery oxygen saturation of 79%. The Swan-Ganz catheter was left in place for hemodynamic monitoring. The pericardial effusion was gradually drained over the course of 2 days to avoid significant impact on right-sided hemodynamics. Interestingly, pulmonary artery oxygen saturation increased to 93% and then to 99% after complete drainage of the effusion. Suspicion of shunt was raised when drainage of pericardial fluid led to serial increases in mixed venous oxygen saturations approaching arterial levels. To evaluate for left-to-right shunt, transesophageal echocardiography (TEE) was performed, which revealed abnormal, high-velocity, turbulent flow arising from a defect in the inferoseptal aspect of the LV outflow tract (LVOT) into the right atrium (RA) during both systole and diastole, consistent with an LVOT-to-RA fistula (direct, type II Gerbode defect) with significant left-to-right shunting (Figure 3). The entry point in the LVOT appeared to be in the immediate location of the proximal edge of the TAVR valve. TR at this time was graded as moderate.Figure 3Transesophageal Echocardiography Midesophageal View (Between 4-Chamber and RVIT Views) Showing the Presence of a Defect in the LVOT With Shunting Into the RALVOT = left ventricular outflow tract; RA = right atrium; RVIT = right ventricular inflow tract. Transesophageal Echocardiography Midesophageal View (Between 4-Chamber and RVIT Views) Showing the Presence of a Defect in the LVOT With Shunting Into the RA LVOT = left ventricular outflow tract; RA = right atrium; RVIT = right ventricular inflow tract. Management Given cardiogenic shock requiring vasopressor support and significant hemolytic anemia, it was decided that closure of the defect was necessary. Multidisciplinary heart team evaluation again found that surgical risk was prohibitive, and a percutaneous approach was chosen. TEE showed the defect to be 9 mm at the widest point. A 14-mm Amplatzer Vascular Plug II (Abbott) was selected (50% larger diameter than the defect), with an atrial septal defect occlusion device with an 8-mm waist as a secondary option. Via the right femoral vein, an Agilis steerable catheter (Abbott) was placed in the RA. Then, using an MPA2 catheter (to direct toward the defect), a Glidewire (Terumo) was advanced across the defect and into the LV. The Glidewire was exchanged for an Amplatz Super Stiff wire (Boston Scientific). The 14-mm Amplatzer Vascular Plug II (Abbott) was initially attempted to be placed but was not well seated and stability was not satisfactory, and the plug was removed. A 7-F Amplatzer septal delivery sheath (Abbott) was then advanced into the LV, and an 8-mm-waist (16-mm RA disc, 20-mm LV disc) Amplatzer septal occluder device (Abbott) was carefully deployed, angled away from the inferior aspect of the bioprosthetic aortic valve to avoid impact on valve function. This device appeared to sit well (Figure 4, see Table 1 for equipment list). The shunt was reduced by at least 80%. A small amount of residual shunting was still seen between the 2 discs. The LV and the RA discs did not appear to interfere with the aortic or the tricuspid valve function.Figure 4LAO Caudal Projection During Deployment of Occluder Device(Left) Positioning of the delivery system and (Right) the deployed occluder device shortly after ventriculogram showing significant reduction in degree of shunting.Table 1Equipment List Used During Initial Percutaneous RepairCatheters/Sheaths/DilatorsWiresDevices, Introducers, and Closure Systems6-F Terumo sheathCordis Emerald J tip guidewire5-F micropuncture transcatheter coaxial introducer8-F Maquet catheterAmplatz Super Stiff guidewireAgilis NxT steerable introducer6-F sheath shuttleTerumo Glidewire 0.038 × 150 cmPerclose ProStyle closure system5-F Cordis Infiniti pigtailAngio-Seal VIP vascular closure device5-F Cordis Infiniti MPA214-mm Amplatzer vascular plug II system10-F Pinnacle sheath8-mm Amplatzer septal occluder deviceAmplatzer Trevisio intravascular delivery system LAO Caudal Projection During Deployment of Occluder Device (Left) Positioning of the delivery system and (Right) the deployed occluder device shortly after ventriculogram showing significant reduction in degree of shunting. Table 1Equipment List Used During Initial Percutaneous RepairCatheters/Sheaths/DilatorsWiresDevices, Introducers, and Closure Systems6-F Terumo sheathCordis Emerald J tip guidewire5-F micropuncture transcatheter coaxial introducer8-F Maquet catheterAmplatz Super Stiff guidewireAgilis NxT steerable introducer6-F sheath shuttleTerumo Glidewire 0.038 × 150 cmPerclose ProStyle closure system5-F Cordis Infiniti pigtailAngio-Seal VIP vascular closure device5-F Cordis Infiniti MPA214-mm Amplatzer vascular plug II system10-F Pinnacle sheath8-mm Amplatzer septal occluder deviceAmplatzer Trevisio intravascular delivery system Equipment List Used During Initial Percutaneous Repair The patient was discharged from the hospital after a brief recovery, however several weeks later he was readmitted given progressive symptoms, persistent anemia requiring serial blood transfusions, and was again in cardiogenic shock requiring vasopressor support. TEE was repeated and showed paradevice flow and reduced RV function with torrential TR (Figure 5). The paradevice flow was coming just inferior to the TAVR prosthesis. The decision was made to revise the defect closure (initially attempted with paradevice plug) as well as to perform tricuspid transcatheter edge-to-edge repair, as the TR was felt to be multifactorial and out of proportion to the shunt alone. Echocardiography showed that the RA was severely enlarged with significant dilatation of the tricuspid annulus and poor coaptation of valve leaflets, resulting in torrential TR. During the initial attempt at this combined procedure, the closure of the residual LVOT-to-RA shunt had to be aborted after multiple failed attempts to wire across the small residual shunt. Attempted transcatheter tricuspid valve edge-to-edge repair was also unsuccessful after failed attempts to adequately secure leaflet capture. It was apparent that it would be impossible to deploy a plug and that device removal and replacement would be necessary.Figure 5Transesophageal Echocardiography Midesophageal View of the Tricuspid ValveTransesophageal echocardiography showing torrential tricuspid regurgitation and residual shunting at the inferior aspect of the occluder device. Transesophageal Echocardiography Midesophageal View of the Tricuspid Valve Transesophageal echocardiography showing torrential tricuspid regurgitation and residual shunting at the inferior aspect of the occluder device. Five days later, while still requiring ongoing vasopressor support, the patient was brought back for a third procedure. The procedure was performed with TEE as well as intracardiac echocardiography guidance, as acoustic windows with TEE were almost perpendicular to the defect, leading to high angle of insonation. An Agilis catheter (Abbott) was again advanced into the RA, and using a gooseneck snare, the initial septal occluder device was snared and removed from the defect; subsequently, it embolized into the right pulmonary artery. A second Amplatzer septal occluder device, selected to be the same size as previously, was then deployed across the Gerbode defect at a more perpendicular angle to the TAVR prosthesis compared to previously, which would result in a better seal at the location of the previous paradevice leak. TEE showed the new device to have excellent positioning and no residual shunting (Figure 6). After closure of the defect, the embolized device was snared from the pulmonary artery and removed from the body via a 14-F Gore DrySeal sheath. A single tricuspid clip was then placed, with capture of the anterior and septal leaflets (see Table 2 for full equipment list). After the edge-to-edge repair, there was reduction in the degree of TR from torrential to severe.Figure 6Transesophageal Echocardiography Midesophageal View Demonstrates Excellent Opposition of the New Septal Occluder DeviceTable 2Equipment List Used During Subsequent Percutaneous Revision and Tricuspid RepairCatheters/Sheaths/DilatorsWiresDevices, Introducers, and Closure Systems8-F Maquet catheterCordis Emerald J tip guidewire5-F micropuncture transcatheter coaxial introducer6-F Cordis Vista Brite guiding catheter MPA1Amplatz Super Stiff guidewirePerclose ProStyle closure systemPhilips VeriSight Pro 3D ICE catheterTerumo Glidewire Exchange angled J10-F Cordis Brite Tip introducer6-F Amplatz Goose Neck snareAgilis NxT steerable introducer6-F Cordis Super Torque diagnostic catheter JR4 532Amplatzer Trevisio intravascular delivery systemEn Snare endovascular snare system8-mm Amplatzer septal occluder device Transesophageal Echocardiography Midesophageal View Demonstrates Excellent Opposition of the New Septal Occluder Device Table 2Equipment List Used During Subsequent Percutaneous Revision and Tricuspid RepairCatheters/Sheaths/DilatorsWiresDevices, Introducers, and Closure Systems8-F Maquet catheterCordis Emerald J tip guidewire5-F micropuncture transcatheter coaxial introducer6-F Cordis Vista Brite guiding catheter MPA1Amplatz Super Stiff guidewirePerclose ProStyle closure systemPhilips VeriSight Pro 3D ICE catheterTerumo Glidewire Exchange angled J10-F Cordis Brite Tip introducer6-F Amplatz Goose Neck snareAgilis NxT steerable introducer6-F Cordis Super Torque diagnostic catheter JR4 532Amplatzer Trevisio intravascular delivery systemEn Snare endovascular snare system8-mm Amplatzer septal occluder device Equipment List Used During Subsequent Percutaneous Revision and Tricuspid Repair Outcome Follow up TTE demonstrated no further shunting and residual moderate TR. The patient recovered in the cardiovascular intensive care unit, improved rapidly, and was discharged from the hospital 10 days later. He was referred to cardiac rehabilitation. At his follow-up appointments, his symptoms showed improvement from NYHA functional class IV to II, and repeat TTE showed stability of aortic bioprosthesis, Gerbode defect closure device, and transcatheter edge-to-edge repair. Discussion Gerbode defect is a congenital or acquired abnormal connection between the left ventricle and the right atrium.1 Etiologies of acquired Gerbode defects have previously been described as rare complications of tricuspid valve endocarditis,2 mitral and tricuspid valve repair,3,4 congenital heart defect repair including tetralogy of Fallot,5 and atrioventricular nodal catheter ablation.6 Classification of Gerbode defect includes a direct supravalvular type via the membranous septum, an indirect infravalvular type, and an intermediate involving both pathways surrounding the tricuspid septal leaflet.7 Without repair, cardiogenic shock, hemolytic anemia, and acute kidney injury may develop; all were seen in this patient.8 Gerbode defect can rarely occur as a complication of aortic valve replacement, with both surgical and transcatheter approaches described.9 Upon review of our patient's initial TAVR planning, his native aortic valve calcium score was 5,324 Agatston units and was suggestive of functional bicuspid valve with fused right and left cusps and dense calcification at the raphe (Figure 7). Aortic annulus was 30 × 27 mm with an area of 608 mm2 and circumference of 89 mm. Coronary artery heights were 12 mm for the left main and 16 mm for the right. Supra-annular measurements at the sinus of Valsalva revealed diameters of 35/34/35 mm. A 29-mm balloon-expandable prosthesis was selected after a multidisciplinary conference. The valve was deployed with a nominal volume with no additional volume added. The deployment was 80:20 in a 3-cusp view. Balloon valvuloplasty was not performed before TAVR. During the initial deployment of the bioprosthetic valve and during postdilation, the bioprosthetic valve was seen to be preferentially expanding away from the fused raphe (green arrow in Figure 8) and toward the noncoronary cusp bordering the interatrial septum (yellow arrow in Figure 8), which likely contributed to erosion and defect creation between the LVOT and RA.Figure 7Computed Tomography of the Native Aortic Valve Before TAVRTAVR = transcatheter aortic valve replacement.Figure 8LAO Caudal Projection Just After Deployment of TAVR BioprosthesisLAO = left anterior oblique; TAVR = transcatheter aortic valve replacement. Computed Tomography of the Native Aortic Valve Before TAVR TAVR = transcatheter aortic valve replacement. LAO Caudal Projection Just After Deployment of TAVR Bioprosthesis LAO = left anterior oblique; TAVR = transcatheter aortic valve replacement. In an era where TAVR and tricuspid repairs are becoming increasingly more common, so too are complications such as Gerbode defects. Minimally invasive repairs of Gerbode defect with percutaneous transcatheter approaches will have to be undertaken, especially in patients at high surgical risk.10 However, they are not always successful and may require revision with further percutaneous device insertions, as seen in this case, or with high-risk surgical patching. Conclusions Gerbode defect is an abnormal LVOT-to-RA connection and can be congenital or acquired after procedures such as TAVR. An underlying bicuspid aortic valve with fused cusps may present an additional risk factor for intraoperative erosion and formation of this defect. Diagnosed best with TEE, this defect can be repaired with the reported percutaneous transcatheter technique. Early recognition, risk assessment, and multidisciplinary approach are crucial for repair.Visual SummaryTimeline of the CaseTimeEventsDay 1A 79-year-old man presented 2 mo after TAVR to his routine follow-up appointment with NYHA functional class III symptoms, decompensated congestive heart failure, and acute kidney injury, prompting admission to the hospital.TTE showed an EF of 40%-45% with new severe tricuspid regurgitation.Day 14Transferred to CCU given poor response to diuretics, development of hypotension, atrial fibrillation with rapid ventricular response, hemolytic anemia, and worsening kidney function.TTE showed well-seated bioprosthetic aortic valve with a mean gradient of 6 mm Hg and calculated valve area of 3.4 cm2; hyperdynamic LV with EF >75%, severe tricuspid regurgitation, and a large, circumferential pericardial effusion.Day 15Right heart catheterization revealed PA oxygen saturation of 79%, which then increased to 93% and then to 99% after drainage of the pericardial effusion over 2 d.Day 18TEE performed identified abnormal, high-velocity, turbulent flow arising from a defect in the inferoseptal aspect of the LVOT into the RA during both systole and diastole, consistent with a fistula (direct, type II Gerbode defect) with significant left-to-right shunting.Day 21Deemed by a multidisciplinary team to be at high risk for open surgical repair.Underwent percutaneous transcatheter closure of the Gerbode defect with an Amplatzer atrial septal occluder device.Day 34Discharged to subacute rehabilitation facility.Day 52Readmitted directly to CCU with cardiogenic shock from decompensated heart failure and acute worsening of chronic hemolytic anemia.Repeat TEE revealed a small paravalvular residual Gerbode defect with preserved EF (65%-70%) and severe tricuspid regurgitation.Day 60Percutaneous tricuspid valve TEER and paradevice leak revision attempted, however aborted given failure to secure leaflet capture and inability to wire across the shunt.Day 66Underwent TEER and replacement of Amplatzer atrial septal occluder device. Procedure complicated by initial device embolization to right PA, which was retrieved successfully. Follow up TTE was without shunting and demonstrated improvement of TR.Day 76Discharged to subacute rehabilitation facility.Day 107Outpatient clinic visit at 30 d postdischarge, deemed improved and stable for yearly follow-up.CCU = cardiac care unit; EF = ejection fraction; LV = left ventricle; LVOT = left ventricular outflow tract; PA = pulmonary artery; RA = right atrium; TAVR = transcatheter aortic valve replacement; TEE = transesophageal echocardiography; TEER = transcatheter edge-to-edge repair; TTE = transthoracic echocardiography; TR = tricuspid regurgitation. Visual SummaryTimeline of the CaseTimeEventsDay 1A 79-year-old man presented 2 mo after TAVR to his routine follow-up appointment with NYHA functional class III symptoms, decompensated congestive heart failure, and acute kidney injury, prompting admission to the hospital.TTE showed an EF of 40%-45% with new severe tricuspid regurgitation.Day 14Transferred to CCU given poor response to diuretics, development of hypotension, atrial fibrillation with rapid ventricular response, hemolytic anemia, and worsening kidney function.TTE showed well-seated bioprosthetic aortic valve with a mean gradient of 6 mm Hg and calculated valve area of 3.4 cm2; hyperdynamic LV with EF >75%, severe tricuspid regurgitation, and a large, circumferential pericardial effusion.Day 15Right heart catheterization revealed PA oxygen saturation of 79%, which then increased to 93% and then to 99% after drainage of the pericardial effusion over 2 d.Day 18TEE performed identified abnormal, high-velocity, turbulent flow arising from a defect in the inferoseptal aspect of the LVOT into the RA during both systole and diastole, consistent with a fistula (direct, type II Gerbode defect) with significant left-to-right shunting.Day 21Deemed by a multidisciplinary team to be at high risk for open surgical repair.Underwent percutaneous transcatheter closure of the Gerbode defect with an Amplatzer atrial septal occluder device.Day 34Discharged to subacute rehabilitation facility.Day 52Readmitted directly to CCU with cardiogenic shock from decompensated heart failure and acute worsening of chronic hemolytic anemia.Repeat TEE revealed a small paravalvular residual Gerbode defect with preserved EF (65%-70%) and severe tricuspid regurgitation.Day 60Percutaneous tricuspid valve TEER and paradevice leak revision attempted, however aborted given failure to secure leaflet capture and inability to wire across the shunt.Day 66Underwent TEER and replacement of Amplatzer atrial septal occluder device. Procedure complicated by initial device embolization to right PA, which was retrieved successfully. Follow up TTE was without shunting and demonstrated improvement of TR.Day 76Discharged to subacute rehabilitation facility.Day 107Outpatient clinic visit at 30 d postdischarge, deemed improved and stable for yearly follow-up.CCU = cardiac care unit; EF = ejection fraction; LV = left ventricle; LVOT = left ventricular outflow tract; PA = pulmonary artery; RA = right atrium; TAVR = transcatheter aortic valve replacement; TEE = transesophageal echocardiography; TEER = transcatheter edge-to-edge repair; TTE = transthoracic echocardiography; TR = tricuspid regurgitation. Timeline of the Case CCU = cardiac care unit; EF = ejection fraction; LV = left ventricle; LVOT = left ventricular outflow tract; PA = pulmonary artery; RA = right atrium; TAVR = transcatheter aortic valve replacement; TEE = transesophageal echocardiography; TEER = transcatheter edge-to-edge repair; TTE = transthoracic echocardiography; TR = tricuspid regurgitation. Funding Support and Author Disclosures Dr Iyer has received compensation from Edwards Lifesciences for speaking and consulting. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.